Amalgamated Bank Increases Position in ABIOMED, Inc. (NASDAQ:ABMD) – Redmond Register

Amalgamated Bank lifted its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 6.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,801 shares of the medical equipment providers stock after purchasing an additional 491 shares during the period. Amalgamated Banks holdings in ABIOMED were worth $1,331,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Lenox Wealth Advisors LLC purchased a new position in shares of ABIOMED in the 4th quarter valued at about $34,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of ABIOMED by 326.4% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 226 shares of the medical equipment providers stock valued at $39,000 after purchasing an additional 173 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in shares of ABIOMED by 638.2% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 251 shares of the medical equipment providers stock valued at $43,000 after purchasing an additional 217 shares in the last quarter. Quadrant Capital Group LLC increased its stake in shares of ABIOMED by 107.1% in the 4th quarter. Quadrant Capital Group LLC now owns 261 shares of the medical equipment providers stock valued at $43,000 after purchasing an additional 135 shares in the last quarter. Finally, Cullen Frost Bankers Inc. purchased a new position in shares of ABIOMED in the 4th quarter valued at about $47,000. Hedge funds and other institutional investors own 98.24% of the companys stock.

Several equities analysts recently weighed in on the company. ValuEngine upgraded ABIOMED from a buy rating to a strong-buy rating in a research note on Monday, March 9th. BTIG Research assumed coverage on ABIOMED in a research note on Thursday, February 6th. They set a hold rating for the company. BidaskClub upgraded ABIOMED from a sell rating to a hold rating in a research note on Friday, January 17th. Finally, Morgan Stanley lowered ABIOMED from an equal weight rating to an underweight rating and cut their price objective for the stock from $198.00 to $165.00 in a research note on Tuesday, February 11th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the companys stock. ABIOMED currently has a consensus rating of Hold and an average price target of $264.00.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $1.51 EPS for the quarter, topping the Thomson Reuters consensus estimate of $1.09 by $0.42. ABIOMED had a return on equity of 19.53% and a net margin of 29.14%. The company had revenue of $221.60 million during the quarter, compared to analyst estimates of $226.92 million. During the same period in the previous year, the business earned $0.97 EPS. ABIOMEDs quarterly revenue was up 10.5% on a year-over-year basis. Analysts anticipate that ABIOMED, Inc. will post 4.12 earnings per share for the current year.

ABIOMED Company Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Featured Story: How are capital gains distributions different for tax-deferred account?

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

The rest is here:
Amalgamated Bank Increases Position in ABIOMED, Inc. (NASDAQ:ABMD) - Redmond Register